Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

476
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
476
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

216
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
216
Neural Regulation01:37

Neural Regulation

39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
Drugs Acting on Autonomic Ganglia: Blockers01:28

Drugs Acting on Autonomic Ganglia: Blockers

958
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
958
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Post-Hypoxic Myoclonus and Deep Brain Stimulation. Experience from a Small Patient Cohort and Literature Review Highlighting Variable Outcomes.

Tremor and other hyperkinetic movements (New York, N.Y.)·2026
Same author

Association of GBA1 status and sex with depression severity and progression in Parkinson's disease.

NPJ Parkinson's disease·2026
Same author

Tracking Genetic Parkinson's Disease with Molecular Imaging: A Systematic Review.

Movement disorders clinical practice·2026
Same author

ChatGPT in the diagnosis and management of complex polyneuropathies: comparative analysis with neurologists using real-world cases.

NPJ digital medicine·2026
Same author

Association between embryologist-related variability in blastocyst vitrification/warming and reproductive outcomes: a single-center retrospective study with external confirmation analysis.

Fertility and sterility·2026
Same author

DPP3 deficiency impacts bone quality and sensitizes to metabolic alterations.

Bone·2026

Related Experiment Video

Updated: Jun 4, 2025

Development of a Unilaterally-lesioned 6-OHDA Mouse Model of Parkinson's Disease
10:09

Development of a Unilaterally-lesioned 6-OHDA Mouse Model of Parkinson's Disease

Published on: February 14, 2012

51.1K

Parasympathetic Dysfunction Prevails in GBA1-Associated Parkinson's Disease.

Tiziana De Santis1,2, Antoniangela Cocco1,3, Paolo Castiglioni4,5

  • 1Department of Neurology, IRCCS Humanitas Research Hospital, Rozzano, Italy.

Movement Disorders Clinical Practice
|December 20, 2024
PubMed
Summary

Parkinson's disease patients with GBA1 gene variants (GBA-PD) show greater autonomic symptoms and impaired parasympathetic function compared to idiopathic Parkinson's disease (I-PD). This highlights cardiovagal dysfunction in GBA-PD.

Keywords:
Parkinson's diseasedysautonomiaglucocerebrosidasenon‐motor symptoms

More Related Videos

Gait Analysis of Age-dependent Motor Impairments in Mice with Neurodegeneration
07:46

Gait Analysis of Age-dependent Motor Impairments in Mice with Neurodegeneration

Published on: June 18, 2018

11.8K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.6K

Related Experiment Videos

Last Updated: Jun 4, 2025

Development of a Unilaterally-lesioned 6-OHDA Mouse Model of Parkinson's Disease
10:09

Development of a Unilaterally-lesioned 6-OHDA Mouse Model of Parkinson's Disease

Published on: February 14, 2012

51.1K
Gait Analysis of Age-dependent Motor Impairments in Mice with Neurodegeneration
07:46

Gait Analysis of Age-dependent Motor Impairments in Mice with Neurodegeneration

Published on: June 18, 2018

11.8K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.6K

Area of Science:

  • Neurology
  • Autonomic Neuroscience

Background:

  • The autonomic nervous system's role in Parkinson's disease (PD) with GBA1 gene variants (GBA-PD) is not well understood.
  • Investigating sympathetic and parasympathetic function is crucial for GBA-PD patient management.

Purpose of the Study:

  • To compare cardiovascular autonomic function between GBA-PD and idiopathic PD (I-PD) patients.
  • To assess autonomic symptoms and cardiac sympathetic innervation in early to mid-stage GBA-PD and I-PD.

Main Methods:

  • Cardiovascular autonomic function tests, including heart rate and blood pressure variability.
  • Cardiac noradrenergic imaging to assess sympathetic nerve activity.
  • SCOPA-AUT questionnaire for autonomic symptom evaluation.

Main Results:

  • GBA-PD patients reported a higher frequency and severity of autonomic symptoms than I-PD patients.
  • GBA-PD showed significantly worse parasympathetic function and reduced heart rate variability (vagal modulation).
  • Sympathetic function and cardiac sympathetic binding were similar between GBA-PD and I-PD groups.

Conclusions:

  • GBA-PD is characterized by significant cardiovagal dysfunction.
  • Autonomic symptom burden is increased in GBA-PD compared to I-PD.
  • Findings suggest a distinct autonomic profile in GBA-PD patients.